Skip to main content
Log in

Graft Versus Host Disease

A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation

  • Original Article
  • Published:
Bone Marrow Transplantation Submit manuscript

Abstract

Tumor necrosis factor (TNF) and Fas ligand (FasL) have been implicated in the pathogenesis of graft- versus-host disease (GVHD), which is a major complication after allogeneic bone marrow transplantation. We have examined the ameliorating effect of a metalloproteinase inhibitor (KB-R7785) that inhibits TNF-α and FasL release in a murine acute GVHD model after bone marrow transplantation. Administration of KB-R7785 to irradiated (BALB/c × C57BL/6) F1 mice that received C57BL/6 bone marrow cells and spleen cells reduced the mortality and weight loss in association with minimal signs of GVHD pathology in the liver, intestine, and hematopoietic tissues. The KB-R7785 treatment did not affect hematopoietic reconstitution by donor cells. Therefore, KB-R7785 could be a potent therapeutic agent for GVHD after bone marrow transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hattori, K., Hirano, T., Ushiyama, C. et al. A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation. Bone Marrow Transplant 23, 1283–1289 (1999). https://doi.org/10.1038/sj.bmt.1701792

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1701792

  • Springer Nature Limited

Keywords

This article is cited by

Navigation